Priaxon Enters Collaboration with GSK on Protein-Protein-Interactions
News Jan 08, 2013
Priaxon has announced a collaboration with GlaxoSmithKline (GSK) to research and develop small molecule modulators of protein-protein-interactions.
Priaxon will provide its innovative and proprietary small molecule drug discovery expertise which is particularly suited to investigating the modulation of protein-protein interactions (PPIs).
PPIs play an important role in many cell signaling pathways and cell-surface receptor-ligand interactions that become dysregulated in disease states.
This collaboration will work to identify and advance candidates from hits to leads for pre-clinical development, with the long term interest of developing and commercializing drug candidates.
The agreement has been signed following a successful pilot project. Financial details as well as therapeutic fields of the collaboration are not disclosed.
"Using the strength of its unique drug discovery platform Priaxplore®, Priaxon will develop new small molecule modulators for hard-to-drug PPI targets," said Dr. Juergen Kolb, CEO of Priaxon.
Dr. Kolb continued, "Our collaboration with GSK and its experts provides the resources and the capabilities to drive these programs forward. We are looking forward to working together with the goal to develop small molecule modulators for various protein-protein interaction of high potential."
Paired Mutations: A New Approach to Discovering the Shape of ProteinsNews
Scientists have identified 'sequence co-variation' by analyzing the repertoire of mutations across thousands of members of a protein family. Within the three-dimensional structure of protein, certain amino acids interact so closely with each other that the mutation of one of them must be counteracted by compensatory mutations of the others to keep the protein functional.READ MORE
New Discoveries in Down's Syndrome ResearchNews
Researchers have discovered that the symptoms of Down's Syndrome are caused by the uncontrolled dysregulation of proteins in the cells. To achieve this, scientists quantified 4,000 out of the 10,000 proteins synthesised by skin cells – a world premiere – using SWATH-MS.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE